Find a cancer clinical trial

Clinical trials provide a great option to get the latest in cancer care, and they don't have to be a last resort.

Hundreds of cancer clinical trials are available now across all points of the cancer journey at each of Mayo Clinic's three campuses in Arizona, Florida and Minnesota and at Mayo Clinic Health System sites throughout the Midwest.

Clinical trials are also available through our partnering organizations. You might even be able to participate in a trial from your own home.

Search the list of studies by cancer type,location, status and more.

Showing 1-10 of 480 open studies

A Study to Evaluate Rectal Cancer with Diffusion-Weighted and Dynamic Contrast Enhanced Perfusion-Weighted Magnetic Resonance Imaging
Jacksonville, FL
The purpose of this study is to analyze the apparent diffusion coefficient (ADC) from Diffusion-Weighted (DWI) in patients before, during the second week of and after preoperative chemoradiation therapy for rectal cancer.
A Study to Evaluate Contouring Organs at Risk for Treatment Planning
Scottsdale/Phoenix, AZ
The purpose of this study is to determine: if the artificial intelligence (AI)-generated results are less arduous than manual tracing by radiation oncologist, and the non-inferiority of the quality of AI vs. manual tracing. These aims will be evaluated in a clinical environment to investigate the impact of an AI algorithm on the clinical workflow. Radiotherapy treatment planning requires precise calculations of radiation exposure, not only for the target volumes (tissue containing malignancy), but of nearby organs-at-risk (OARs), in which the exposure needs to be minimized. Manual segmentation of these organs is a time-consuming task with high interobserver variability. Producing these segmentations automatically will reduce the time required for treatment planning and improve the interobserver variability.
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Scottsdale/Phoenix, AZ
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.
A Study to Evaluate Circulating Cell Free Tumor DNA as a Biomarker in Sarcoma
Rochester, MN
The purpose of this study is to determine the feasibility of ctDNA detection in patients with advanced translocation-associated sarcomas.
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Scottsdale/Phoenix, AZ
The purpose of this study is to to characterize the safety, tolerability, and pharmacokinetics of MRTX1719 in patients with advanced solid tumor malignancies with MTAP (methylthioadenosine phosphorylase) deletion.
A Study to Determine Baseline Levels for Prostate Cancer-Derived Particles Containing Cellular Matter (Extracellular Vesicles) After Local Treatment
Rochester, MN
The purposes of this study are to determine the levels of prostate cancer-derived extracellular vesicles pre- and post-local therapy (radical prostatectomy or radiation therapy), to correlate analysis for PSA levels and prostate cancer-derived extracellular vesicles, and to determine baseline levels of prostate cancer-derived extracellular vesicles in patients undergoing different lines of primary local treatment.
A Study of ONO-7475 in Patients With Acute Leukemias
Jacksonville, FL
The purpose of this study is to assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes, and to assess the safety, tolerability, and preliminary effectiveness of the combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid leukemia.
A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Scottsdale/Phoenix, AZ
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA&reg;]), gemcitabine or vinorelbine (NAVELBINE&reg;).
A Registry to Collect Patient and Family DNA and Information for Anyone who has had Multiplex Testing and Gene Mutation Results
Rochester, MN
The purpose of this study is to collect patient and family DNA and disease data to learn more about how changes in certain genes may be linked to cancer. Some people with cancer may have aquired their disease because they inherited an abnormal (mutated) gene. The researchers of this study want to better understand the risks that are linked to genetic changes in these less well-studied genes. By understanding these risks, it is believed that doctors will be able to give better advice to families with mutations in these genes.
Phase I Trial of Sargramostim and Nivolumab for Metastatic Melanoma to the Lung
Rochester, MN
This phase I trial is looking to see if sargramostim given with a nebulizer, in combination with standard immune checkpoint inhibitor therapy with nivolumab can help control melanoma that has metastasized to the lungs.